Ube to absorb APIC

Japan’s Ube Chemical has decided to merge by absorption API Corporation (APIC), the CDMO operation it acquired from Mitsubishi Chemical in December 2022. This will take effect on 1 December 2024 and is expected to have only a minimal impact on Ube’s consolidated earnings.

The company said that it made this decision in order to “further promote the sharing of the proprietary high-level manufacturing and quality control technologies of both companies, accelerate the development of new technologies, expand supply chain networks and leverage the existing bases of both companies”.

Ube has already been integrating its own pharma operations with APIC, which offers synthetic route design, research, pilot manufacturing and commercial production, based on integrated processes that combine organic synthesis and biotechnologies. APIC also makes APIs and intermediates using processes based on its proprietary technologies.